Ceftobiprole medocaril: a new generation beta-lactam.

Area of Science:

• Pharmacology
• Infectious Diseases
• Microbiology

Background:

• Ceftobiprole is a novel parenteral cephalosporin with broad-spectrum activity.
• It exhibits high affinity for penicillin-binding proteins, including PBP2a, conferring activity against methicillin-resistant staphylococci (MRSA).
• Its stability against various beta-lactamases and favorable pharmacokinetic profile position it as a promising antimicrobial agent.

Purpose of the Study:

• To evaluate the efficacy and safety of ceftobiprole medocaril in treating complicated skin and skin structure infections.
• To assess its potential as monotherapy for infections typically requiring combination treatment, particularly those involving MRSA.

Main Methods:

• Ceftobiprole medocaril, administered intravenously as a prodrug due to low water solubility, was evaluated in two Phase III clinical trials.
• The study focused on its in vitro activity against key pathogens and its clinical performance in treating skin infections.

Main Results:

• Ceftobiprole demonstrated potent in vitro activity against staphylococci and multiresistant pneumococci.
• Its Gram-negative spectrum is comparable to other extended-spectrum cephalosporins.
• Phase III trials indicated ceftobiprole medocaril is generally well-tolerated, with taste disturbance as a notable side effect.

Conclusions:

• Ceftobiprole medocaril is an effective and well-tolerated option for complicated skin infections.
• Its broad spectrum, including MRSA coverage, may enable its use as monotherapy, potentially simplifying treatment regimens.